This is a 24-week study to check how well a medicine called BLU-5937 works and how safe it is for adults who have a cough that doesn't go away, called Refractory Chronic Cough (RCC). The study is randomized, meaning participants are chosen by chance, and double-blind, so neither the participants nor the researchers know who is getting BLU-5937 or a placebo (a fake treatment). The main goal is to see if BLU-5937 reduces coughs over 24 hours after 24 weeks. People can join if they have had RCC for at least a year and can give consent. Women who can have babies must use good birth control. People who smoke, have certain lung diseases, recent infections, or certain other health issues cannot join.

• The study lasts for 24 weeks.
• Participants need to follow specific health guidelines.
• Eligible participants should not have recent serious health issues.